The Galleri Multicancer Early Detection Blood Test
Desert Regional Medical Center is collaborating with Grail, a leading health company, to offer the Galleri multicancer early detection blood test. This innovative blood test can identify signals in the bloodstream that may indicate the presence of cancer cells. Unlike previous screenings, Galleri detects abnormal DNA circulating in the blood that can detect a common cancer signal across more than 50 types of cancers, including pancreatic and ovarian cancers which have no common screening tools available.
The patient’s doctor receives a report indicating if there were or weren’t cancer signals detected in the blood sample as well as identifying one or two locations where the cancer signal may be coming from. However, this test is not recommended for those undergoing active cancer treatment or pregnant women. Moreover, the ideal candidate for this test is someone aged 50 or older who has smoked in the past, has a poor diet or has a family history of cancer.
While the American Cancer Society has laid out guidelines on cancer screenings by age; the Galleri test is considered an additional tool to detect early-stage cancers.
The Holy Grail of Cancer Medicine
The early detection of cancer has been considered as the “holy grail” of cancer medicine. The development of a new blood test offers new hope. In India, Tzar Labs and Epigeneres Biotech have developed an innovative blood test that predicts tumor formation before it occurs. This novel blood test is capable of identifying cancer up to 18 months before its onset and can predict whether stem cells are fated to become cancerous up to 18 months in advance.
A Game Changer in Cancer Medicine
The new blood test designed by Tzar Labs and Epigeneres Biotech detects early signs of tumor formation by focusing on stem cells with specific genetic markers that prompt tumor formation. This test can determine whether cancer is on the horizon well before those cells have progressed to form a tumor, and it can also see cancer at Stages 1 or 2.
In a trial involving 1,000 participants consisting of both cancer and non-cancer patients, this new test correctly anticipated tumors across 25 different types of cancer with zero false positives or negatives. The test can say exactly which organ the would-be tumor cells will target, noninvasively and well before the first tumor has accumulated.
Furthermore, this blood test is repeatable and can be used to track the success of cancer treatment. Its developers hope that the test will be performed once a year to catch cancer at Stage 1 or before, when it is infinitely more curable.
Implementation in the UK
Hospitals in the UK have already begun implementing this technique for further proof of concept. Researchers are optimistic about taking the test to the United States soon. The approach differs from other blood-based cancer screening methods by looking for stem cells with a biomarker for cancer rather than searching for full-blown tumor cells that may already be present.
Conclusion:
The development of these innovative blood tests provides new hope in early cancer detection. The Galleri test detects abnormal DNA circulating in the blood while Tzar Labs and Epigeneres Biotech’s new blood test anticipates tumor formation up to 18 months in advance. Both tests can identify various types of cancers at Stages 1 or 2, enhancing their potential in offering an additional tool for early detection alongside current screening guidelines outlined by healthcare agencies. Early detection is critical as it increases patient survival rates and expands options for effective treatments, potentially saving thousands of lives each year.
Image Source: Wikimedia Commons
